<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03151577</url>
  </required_header>
  <id_info>
    <org_study_id>2016-02077</org_study_id>
    <nct_id>NCT03151577</nct_id>
  </id_info>
  <brief_title>Longitudinal Study on Glaucoma Surgery Using XEN® Gel Stent</brief_title>
  <official_title>Longitudinal Study on Glaucoma Surgery Using XEN® Gel Stent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Vision Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Vision Network</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of the XEN® Gel Stent in mild to moderate glaucoma
      patients undergoing glaucoma surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the safety and efficacy of the XEN® Gel Stent in mild to moderate glaucoma
      patients undergoing glaucoma surgery.

      Follow-up period is 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Anticipated">May 31, 2018</completion_date>
  <primary_completion_date type="Actual">January 31, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Intraocular pressure, adverse events, complications, number of medications in mild to moderate glaucoma patients who underwent XEN® Gel Stent implantation were recorded.
Data were collected in a 2 years follow-up.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>Day 0 (=Baseline=before surgery), after surgery on day 1, day 3, week 1, month 1, month 3, month 6, year 1, year 2</time_frame>
    <description>Change in IOP before and after XEN® Gel Stent implantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of needlings</measure>
    <time_frame>2 years</time_frame>
    <description>Number of needlings performed during the follow-up after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of antiglaucomatous medications</measure>
    <time_frame>Day 0 (=Baseline=before surgery), after surgery on day 1, day 3, week 1, month 1, month 3, month 6, year 1, year 2</time_frame>
    <description>Change in number of antiglaucomatous medications before and after the surgery.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Glaucoma</condition>
  <condition>Glaucoma, Open-Angle</condition>
  <condition>Glaucoma, Angle-Closure</condition>
  <condition>Glaucoma, Primary Open Angle</condition>
  <arm_group>
    <arm_group_label>Evolution of IOP after XEN® Gel Stent implantation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>To study the efficacy of the XEN® Gel Stent in lowering the IOP.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>XEN® Gel Stent implantation</intervention_name>
    <description>Minimally invasive glaucoma surgery (MIGS) which consists of implanting a XEN® Gel Stent in the irido-corneal angle of the eye to drain the aqueous humour in the sub-conjunctival space to lower the IOP.</description>
    <arm_group_label>Evolution of IOP after XEN® Gel Stent implantation</arm_group_label>
    <other_name>XEN® Gel Stent, Aquesys</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mild to moderate glaucoma patients

          -  Have given written informed consent

          -  Aged 18 years or older of either sex

        Exclusion Criteria:

          -  Patients not able to understand the character of the study

          -  Participation in other clinical research within the last 4 weeks

          -  Patients with end-stage glaucoma

          -  Patients with glaucoma surgery done before
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2017</study_first_submitted>
  <study_first_submitted_qc>May 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2017</study_first_posted>
  <last_update_submitted>May 11, 2017</last_update_submitted>
  <last_update_submitted_qc>May 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Swiss Vision Network</investigator_affiliation>
    <investigator_full_name>dr. Kaweh Mansouri</investigator_full_name>
    <investigator_title>MD, MPH</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Glaucoma, Angle-Closure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

